Recognition and management of inferior wall myocardial infarctions and right ventricular infarcts

Journal of Intravenous Nursing

Volumn 24, Issue 4, 2001, Pages 263-267

  Scroggins, Nancy M ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

DIFFERENTIAL DIAGNOSIS; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART VENTRICLE; HUMAN; HYPOTENSION; METHODOLOGY; MORBIDITY; PATHOPHYSIOLOGY; REVIEW; UNITED STATES;

ARRHYTHMIA; DIAGNOSIS, DIFFERENTIAL; HEART VENTRICLES; HUMANS; HYPOTENSION; MORBIDITY; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; UNITED STATES;

EID: 0035407734     PISSN: 08965846     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200107000-00011     Document Type: Article

References (14)

1. American Heart Association. 2001 heart and stroke statistical update. Available at: http://www.americanheart.org/statistics. Accessed February 2001.
2. Gaziano JM. Evidence-based classification of CHD risk factors. Cardiovascular Disease Management. 1997;July:1-4.
3. Cicciu JV. Coronary artery disease. In: Kinney MR, Packa DR, Dunbar SB, eds. AACN's Clinical Reference for Critical Care Nursing. 3rd ed. St. Louis: Mosby; 1993.
4. Haji S, Movahed A. Right ventricular infarct: diagnosis and treatment. Clin Cardiol. 2000;23:473-482.
5. Ryan TJ, Antman EM, Brooks NA, et al. ACC/AHA guidelines for the management of patients with acute MI: executive summary and recommendations. Circulation. 1999;100:1016-1030.
6. O'Rourke RA. Treatment of right ventricular infarction: thrombolytic therapy, coronary angioplasty, or neither. J Am Coll Cardiol. 1998;32:882-884.
7. Scroggins N. Hemorrhagic disorders associated with thrombolytic therapy. Critical Care Nursing Clinics of North America. 2000;12(3):353-363.
8. Zehender M, Kasper W, Kander E, et al. Eligibility for and benefit of thrombolytic therapy in inferior myocardial infarction: focus on the prognostic importance of RVI. J Am Coll Cardiol. 1994;24(2):326-329.
9. Scroggins N. Platelet glycoprotein IIb/IIIa receptor antagonist use in acute coronary syndromes. AACN Critical Care Critical Issues: Houston Gulf Coast Chapter Newsletter. 2000;September.
10. Ghaffari S, Kereiakes DJ, Lincoff AM, et al, with EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. Evaluation of PTCA to improve long-term outcome by c7E3 GP IIb/IIIa receptor blockade. Am J Cardiol. 1998;82(1):7-12.
11. Hamm CW, Heeschen C, Goldmann B, et al, with CAPTURE Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med. 1999;340(21):1623-1629.
12. Mahaffery KW, Harrington RA, Simoons ML, et al, with PURSUIT Investigators. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 1999;99(18):2371-2377.
13. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338: 1499-1497.
14. Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to minimize platelet. 1999; J Am Coll Cardiology. 33(1):88-96.